Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Legacy data sharing to improve drug safety assessment: the eTOX project.

Sanz F, Pognan F, Steger-Hartmann T, Díaz C; eTOX, Cases M, Pastor M, Marc P, Wichard J, Briggs K, Watson DK, Kleinöder T, Yang C, Amberg A, Beaumont M, Brookes AJ, Brunak S, Cronin MTD, Ecker GF, Escher S, Greene N, Guzmán A, Hersey A, Jacques P, Lammens L, Mestres J, Muster W, Northeved H, Pinches M, Saiz J, Sajot N, Valencia A, van der Lei J, Vermeulen NPE, Vock E, Wolber G, Zamora I.

Nat Rev Drug Discov. 2017 Dec;16(12):811-812. doi: 10.1038/nrd.2017.177. Epub 2017 Oct 13.

PMID:
29026211
2.

Inroads to predict in vivo toxicology-an introduction to the eTOX Project.

Briggs K, Cases M, Heard DJ, Pastor M, Pognan F, Sanz F, Schwab CH, Steger-Hartmann T, Sutter A, Watson DK, Wichard JD.

Int J Mol Sci. 2012;13(3):3820-46. doi: 10.3390/ijms13033820. Epub 2012 Mar 21. Review.

3.

Improving the Safety Assessment of Chemicals and Drug Candidates by the Integration of Bioinformatics and Chemoinformatics Data.

Steger-Hartmann T, Pognan F.

Basic Clin Pharmacol Toxicol. 2018 Sep;123 Suppl 5:29-36. doi: 10.1111/bcpt.12956. Epub 2018 Feb 6. Review.

PMID:
29316298
4.

Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.

Benjamin A, Gallacher DJ, Greiter-Wilke A, Guillon JM, Kasai C, Ledieu D, Levesque P, Prelle K, Ratcliffe S, Sannajust F, Valentin JP.

J Pharmacol Toxicol Methods. 2015 Sep-Oct;75:101-10. doi: 10.1016/j.vascn.2015.01.004. Epub 2015 Jan 29.

PMID:
25637943
5.

The eTOX data-sharing project to advance in silico drug-induced toxicity prediction.

Cases M, Briggs K, Steger-Hartmann T, Pognan F, Marc P, Kleinöder T, Schwab CH, Pastor M, Wichard J, Sanz F.

Int J Mol Sci. 2014 Nov 14;15(11):21136-54. doi: 10.3390/ijms151121136.

6.

How do the top 12 pharmaceutical companies operate safety pharmacology?

Ewart L, Gallacher DJ, Gintant G, Guillon JM, Leishman D, Levesque P, McMahon N, Mylecraine L, Sanders M, Suter W, Wallis R, Valentin JP.

J Pharmacol Toxicol Methods. 2012 Sep;66(2):66-70. doi: 10.1016/j.vascn.2012.03.004. Epub 2012 Apr 1.

PMID:
22510338
7.

Understanding drug targets: no such thing as bad news.

Roberts RA.

Drug Discov Today. 2018 Dec;23(12):1925-1928. doi: 10.1016/j.drudis.2018.05.028. Epub 2018 May 24.

PMID:
29803936
8.

The Critical Path to New Medicines: data sharing.

[No authors listed]

Altern Lab Anim. 2006 Jun;34(3):273-4. No abstract available.

PMID:
16874922
9.

Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies.

Hornberg JJ, Laursen M, Brenden N, Persson M, Thougaard AV, Toft DB, Mow T.

Drug Discov Today. 2014 Aug;19(8):1137-44. doi: 10.1016/j.drudis.2013.12.009. Epub 2013 Dec 25. Review.

PMID:
24374152
10.

Generating Modeling Data From Repeat-Dose Toxicity Reports.

López-Massaguer O, Pinto-Gil K, Sanz F, Amberg A, Anger LT, Stolte M, Ravagli C, Marc P, Pastor M.

Toxicol Sci. 2018 Mar 1;162(1):287-300. doi: 10.1093/toxsci/kfx254.

11.

Animal intelligence.

Hoag H.

Nature. 2006 May 25;441(7092):544-5. No abstract available.

PMID:
16789060
12.

Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.

Vanderwall DE, Yuen N, Al-Ansari M, Bailey J, Fram D, Green DV, Pickett S, Vitulli G, Luengo JI, Almenoff JS.

Drug Discov Today. 2011 Aug;16(15-16):646-53. doi: 10.1016/j.drudis.2011.05.001. Epub 2011 May 11.

PMID:
21601652
13.

Methodological innovations expand the safety pharmacology horizon.

Pugsley MK, Curtis MJ.

J Pharmacol Toxicol Methods. 2012 Sep;66(2):59-62. doi: 10.1016/j.vascn.2012.05.004. Epub 2012 May 20.

PMID:
22617368
14.

The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative.

Ewart L, Aylott M, Deurinck M, Engwall M, Gallacher DJ, Geys H, Jarvis P, Ju H, Leishman D, Leong L, McMahon N, Mead A, Milliken P, Suter W, Teisman A, Van Ammel K, Vargas HM, Wallis R, Valentin JP.

Toxicol Sci. 2014 Dec;142(2):427-35. doi: 10.1093/toxsci/kfu198. Epub 2014 Sep 21.

PMID:
25246669
15.

In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practices.

Valentin JP, Guillon JM, Jenkinson S, Kadambi V, Ravikumar P, Roberts S, Rosenbrier-Ribeiro L, Schmidt F, Armstrong D.

J Pharmacol Toxicol Methods. 2018 Sep - Oct;93:7-14. doi: 10.1016/j.vascn.2018.07.001. Epub 2018 Jul 17.

PMID:
30030184
16.

Value of shared preclinical safety studies - The eTOX database.

Briggs K, Barber C, Cases M, Marc P, Steger-Hartmann T.

Toxicol Rep. 2014 Dec 18;2:210-221. doi: 10.1016/j.toxrep.2014.12.004. eCollection 2015.

17.

Drug Safety and Pharmacovigilance--second annual marcus evans conference.

Goldman M.

IDrugs. 2007 Mar;10(3):165-8. No abstract available.

PMID:
17351867
18.

Risk reduction in drug discovery and development.

Mackay M, Street SD, McCall JM.

Curr Top Med Chem. 2005;5(11):1087-90.

PMID:
16181133
19.

[Making Patient-focused Information Provision a Reality: One Company's Approach].

Takemoto S.

Yakugaku Zasshi. 2018;138(3):315-323. doi: 10.1248/yakushi.17-00185-3. Review. Japanese.

20.

Assessing drug safety in human tissues - what are the barriers?

Holmes A, Bonner F, Jones D.

Nat Rev Drug Discov. 2015 Aug;14(8):585-7. doi: 10.1038/nrd4662. Epub 2015 Jul 24. No abstract available.

PMID:
26205467

Supplemental Content

Support Center